Assessment of Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, as a Perpetrator of Clinical Drug Interactions: A Study on Drug Transporters and Metabolic Enzymes
Journal of Diabetes & Metabolism
doi 10.4172/2155-6156.1000200
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2012
Authors
Publisher
OMICS Publishing Group